Elevating patient health: advanced taste capabilities, CBD- based formulations, and pharma expert services from dsm- firmenich at CPHI 2024

This October, dsm-firmenich, innovators in nutrition, health, and beauty, invites stakeholders across the pharmaceutical industry to immerse themselves in its patient-inspired innovations at CPHI 2024.

dsm-firmenich Announces New Vice President of Global Commercial in Biomedical Division

The Biomedical division of dsm-firmenich is thrilled to announce the advancement of Robyn Wiseman to the role of Vice President of Global Commercial. Beginning August 26, 2024, Robyn will lead the global commercial team located throughout the Americas, EMEA, and APAC.

dsm-firmenich secures UK and EU approvals for 3-FL and LNFP-I/2'-FL human milk oligosaccharide ingredients

dsm-firmenich, a global innovator in health, nutrition and beauty, today announced the successful approval of its human milk oligosaccharide (HMO): 3-fucosyllactose (3-FL) and lacto-N-fucopentaose I/2'-fucosyllactose (LNFP-I/2'-FL) mixture as novel food ingredients in the United Kingdom and European Union.

dsm-firmenich Announces Successful Defense of Patent Protecting Its Medical-Grade Colored Yarn Products

dsm-firmenich announces that the United States Patent and Trademark Office (USPTO) rejected Honeywell’s request for inter partes review (IPR) and cancellation of dsm-firmenich’s U.S. Patent No. 10,280,532, claiming a colored multi-filament yarn. The protected inventions are useful in medical devices, such as colored Ultra High Molecular Weight Polyethylene (UHMWPE) sutures.

dsm-firmenich Announces Paul Spencer as new President of Biomedical Business

Following an extensive global search process conducted by Legacy MEDSearch, dsm-firmenich is thrilled to announce the appointment of Paul Spencer as the new President of the Biomedical business. Spencer will replace former President, John Witkowski.

dsm-firmenich to elevate patient health with launch of advanced formulated CBD drug product intermediate - CBtru®

dsm-firmenich has announced the launch of CBtru® – an advanced formulated cannabidiol (CBD) drug product intermediate designed for oral solid delivery formats.

dsm-firmenich and Indena to debut pioneering biotic and botanical combination concepts at Vitafoods Europe 2024 | dsm-firmenich Health, Nutrition & Care

dsm-firmenich and Indena will introduce dietary supplement solutions combining biotics with botanicals in enjoyable delivery formats, offering an enhanced flavor and taste experience, at Vitafoods Europe 2024.

dsm-firmenich marks milestone in ampli-D® authorization with eu approval of calcidiol as a novel food | dsm-firmenich Health, Nutrition & Care

dsm-firmenich, innovators in nutrition, health, and beauty, has announced the approval of its ampli-D® calcidiol monohydrate ingredient as a novel food in the EU by the European Commission.

dsm-firmenich and Lallemand Health Solutions unite to launch synergistic synbiotic solutions for early life nutrition

dsm-firmenich, innovators in nutrition, health and beauty, and Lallemand Health Solutions, pioneers in probiotics, today announce a groundbreaking partnership to launch new synergistic synbiotic solutions for early life nutrition.

dsm-firmenich partners with SCN BestoCo to inspire a new era in omega-3 gummy innovation

dsm-firmenich, the leading innovator in health, nutrition and beauty, has announced an exciting new partnership with SCN BestCo to develop and market advanced omega-3 gummies in the US.

Biomedical expands manufacturing footprint through investment in new

dsm-firmenich successfully defends patent directed to proprietary DHA oils

dsm-firmenich, a leading innovator in nutrition, health, and beauty, is pleased to announce a victory that it prevailed before the United States Patent and Trademark Office (USPTO) today, by successfully defending a patent from an invalidation action recently levied by Mara Renewables Corporation.

Nurturing the future: dsm firmenich announces approval of HMO ingredients for infant nutrition innovation in Australia and New Zealand

dsm-firmenich, a leading innovator in health, nutrition and beauty, is delighted to announce that it has gained approval for an additional four human milk oligosaccharide (HMO) ingredients for use as nutritive substances in infant formula products in Australia and New Zealand.

dsm-firmenich secures 3-fucosyllactose market access in the European Union

dsm-firmenich, a leading innovator in health, nutrition and beauty, announced that it has secured market access for its 3-fucosyllactose (3-FL) human milk oligosaccharide (HMO) ingredient in the European Union (EU).

Indena & dsm-firmenich pioneer a new “age of nature” through selected market-inspired botanical solutions for human health

Indena, a private Italian company with a century of experience in the identification, development and production of high-quality, innovative and effective active botanical principles for the pharmaceutical and health food industries, and dsm-firmenich, innovators in nutrition, health and beauty, have announced a strategic partnership in some specific areas.

dsm-firmenich announces the upcoming launch of life’s®OMEGA O3020

dsm-firmenich, the leading innovator in health, nutrition and beauty, today announces the upcoming North American launch of life’s®OMEGA O3020, the first and only single-source algal omega-3 with the same eicosapentaenoic acid (EPA) to docosahexaenoic acid (DHA) ratio naturally found in standard fish oil, but with twice the potency.

dsm-firmenich partners with bod science to advance science behind first ever cbd-based treatment for insomnia

dsm-firmenich is proud to announce its strategic partnership with Bod Science, an Australian-based pioneer in medical cannabis.

dsm-firmenich to debut at CPhI, sharing its vision for purpose-powered solutions for the pharmaceutical industry

Following the merger of two iconic companies – DSM and Firmenich – in May 2023, dsm-firmenich will make its debut at CPHI Barcelona 2023, showcasing its combined strength as an innovator in health, nutrition and care.

Biomedical joins with the Institute for Complex Molecular Systems (ICMS)

dsm-firmenich boosts HMO portfolio with US FDA 'no questions' letters to GRAS notifications for LNFP-l/2’-FL and hypoallergenic grade LNnT and 2’-FL

dsm-firmenich, innovator in health, nutrition and beauty, today announced that it has received ‘no questions’ response letters from the US Food and Drug Administration (FDA) to its Generally Recognized as Safe (GRAS) notices submitted by Glycom A/S* for three new human milk oligosaccharide (HMO) ingredients.

dsm-firmenich leads global HMO approvals with 2’-FL and LNnT regulatory milestone in China

dsm-firmenich, the leading innovator in health, nutrition and beauty, today announced that its human milk oligosaccharide (HMO) ingredients, GlyCare™ 2’-fucosyllactose (2’-FL) and lacto-N-neotetraose (LNnT), have been approved as food additives (nutrition fortifiers) in China.

dsm-firmenich champions proactive health and delivers solutions by combining the essential, desirable and sustainable at SupplySide West 2023

dsm-firmenich, the leading innovator in health, nutrition and beauty, is to showcase how it is “bringing progress to life” in the human health arena at SupplySide West 2023 – spotlighting its purpose-led innovation platforms to deliver solutions for gut support, cognitive performance, and women’s wellness.

dsm-firmenich takes further steps to bring leading HMO portfolio to China

dsm-firmenich, the leading innovator in health, nutrition and beauty, confirmed plans to expand its human milk oligosaccharide (HMO) portfolio in China with two new ingredient submissions to the China National Center for Food Safety Risk Assessment (CFSA) and National Health Committee (NHC).

dsm-firmenich completes acquisition of postbiotics pioneer Adare Biome

dsm-firmenich, innovators in nutrition, health, and beauty, confirms the completion of its acquisition of Adare Biome, a pioneer in the development and manufacturing of postbiotics, for an enterprise value of €275 million.

dsm-firmenich at Vitafoods 2023: Discover end-to-end solutions powering a sustainable future for nutrition

Royal dsm-firmenich, a global science-based company active in Health, Nutrition & Bioscience, is to reveal its latest purpose-led concepts for fast-tracked nutrition innovation across all life stages at Vitafoods Europe 2023.

Biomedical Introduces Sustainability Initiative for Dyneema Purity® UHMWPE

Hologram Sciences enters partnership with Haleon in the United States

Hologram Sciences, a consumer-facing health tech company building holistic personalized nutrition solutions, and Haleon (NYSE: HLN), a global leader in consumer health, have entered into a strategic collaboration focused on innovation to address consumer health concerns in areas such as healthy aging.

New study reveals DSM’s Fruitflow® activates gut-heart axis with polyphenol-rich extracts that can modulate gut microbiota leading to cardiovascular benefits

Royal DSM, a global, purpose-led, science-based company, partnered with Atlantia Clinical Trials Ltd., a world leading contract research organisation to explore the potential benefits of DSM’s Fruitflow® on gut microbiota and cardiovascular health through the gut-heart axis.

DSM’S HMO (2FL) gains regulatory approval for early life nutrition in Canada

Royal DSM, a global science-based company active in Health, Nutrition and Bioscience, today announced that its human-identical milk oligosaccharide (HMO) GlyCare™ 2’-fucosyllactose (2FL) has been approved in Canada for use in infant formula and nutritional supplements (toddler formula).

DSM announces new partnership with LBB Specialties for North America dietary supplements distribution

Royal DSM, a global science-based company active in Health, Nutrition & Bioscience, forms a new strategic partnership with LBB Specialties (LBBS), a leader in North American specialty chemical and ingredients distribution. The agreement will leverage LBB Specialties’ market expertise to improve customer service levels and increase market share for DSM’s broad ingredient offering for the North American dietary supplements market.

New study links COVID-19 to increased risk of neurological disorders – could omega-3s be a potential nutritional solution?

Royal DSM, a global science-based company active in Health, Nutrition and Bioscience, comments on the findings from a recently published paper in Nature Medicine which reported that those infected with COVID-19 are at increased risk of long-term neurologic disorders that persist post infection. These symptoms are one part of what is now known as “long COVID”, which is estimated to impact 7.5% of adults in the total US population.

Hologram Sciences and Maeil Health Nutrition enter strategic partnership to bring personalized nutrition services to Korea

Hologram Sciences, a consumer-facing personalized nutrition company, and Maeil Health Nutrition, a leader in functional nutrition, are joining forces in a strategic partnership to deliver personalized nutrition solutions to the Korean market.

DSM puts spotlight on protecting the marine ecosystem with newly expanded algal omega-3 portfolio

DSM announces the launch of a new sustainably-focused campaign that encourages the use of algae-derived omega-3 ingredients. DSM aims to educate global audiences on the impact of overfishing on the marine ecosystem.

Biomedical and Svelte Medical Systems

Biomedical and Svelte Medical Systems Collaboration Fuels Development of DISCREET Bioresorbable Coating Technology Used with SLENDER IDS® and DIRECT RX® Bioresorbable Coated Drug-Eluting Stent (DES) Systems

Hologram Sciences unveils new initiatives to transform wellness through personalized health & nutrition

Hologram Sciences, the personalized nutrition pioneer, is targeting a revolution in health & wellness with the unveiling of its new consumer brand concepts addressing key health concerns through novel data-driven approaches.

DSM strengthens end-to-end gut health solutions in North American market

Royal DSM, a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living, today announced that it has bolstered its capabilities as an end-to-end partner for North American customers in the gut health space with FDA NDI status strains.

Biomedical and NC Biomatrix Sign Memorandum of Understanding

dsm-firmenich and OMG Pharma form strategic collaboration to advance first-of-a-kind CBD-based drugs for insomnia

dsm-firmenich is proud to announce its new strategic collaboration with Oz Medicann Group (OMG), to explore the therapeutic potential of cannabidiol (CBD) bases orally dispersible tablets addressing insomnia.

dsm-firmenich partners with Zerion Pharma a/s to unlock superior patient-centric cannabinoid formulations

dsm-firmenich is proud to announce its strategic partnership with Zerion Pharma, to unlock a new era in cannabinoid innovation.

Archive